% | $
Quotes you view appear here for quick access.

Regeneron Pharmaceuticals, Inc. Message Board

  • faosto faosto Nov 16, 2012 2:17 PM Flag

    Another way to look at REGN

    Most of the M&A talk surrounding REGN centers on REGN being bought out by SNY or other large pharma, but I think REGN may soon become a buyer itself of smaller companies. It will soon have a $20 billion market cap, easily capable of swallowing small promising companies with a phase 3 or even approved drug for $2-3 billion a clip in all-stock transactions. On the cholesterol front, it looks like REGN727 is more effective than Amgen's, but less than Pfizer's. However, REGN will be first to market and should capture a significant chunk of that market.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
399.38-3.59(-0.89%)Aug 29 4:00 PMEDT